Literature DB >> 27894960

Cancer stem cells in osteosarcoma.

Hannah K Brown1, Marta Tellez-Gabriel2, Dominique Heymann3.   

Abstract

Osteosarcoma is the most common primary bone tumour in children and adolescents and advanced osteosarcoma patients with evidence of metastasis share a poor prognosis. Osteosarcoma frequently gains resistance to standard therapies highlighting the need for improved treatment regimens and identification of novel therapeutic targets. Cancer stem cells (CSC) represent a sub-type of tumour cells attributed to critical steps in cancer including tumour propagation, therapy resistance, recurrence and in some cases metastasis. Recent published work demonstrates evidence of cancer stem cell phenotypes in osteosarcoma with links to drug resistance and tumorigenesis. In this review we will discuss the commonly used isolation techniques for cancer stem cells in osteosarcoma as well as the identified biochemical and molecular markers.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Bone cancer; Cancer stem cell; Osteosarcoma; Tumour heterogeneity

Mesh:

Substances:

Year:  2016        PMID: 27894960     DOI: 10.1016/j.canlet.2016.11.019

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  74 in total

1.  Novel agent DMAMCL suppresses osteosarcoma growth and decreases the stemness of osteosarcoma stem cell.

Authors:  Gen Ba; Zhongyan Hua; Ning Xu; Simeng Zhang; Zhihui Liu; Carol J Thiele; Zhijie Li
Journal:  Cell Cycle       Date:  2020-05-13       Impact factor: 4.534

Review 2.  Understanding pancreatic cancer stem cells and their role in carcinogenesis: a narrative review.

Authors:  Vikram Sumbly; Ian Landry
Journal:  Stem Cell Investig       Date:  2022-01-19

3.  Tumor-associated macrophages in osteosarcoma.

Authors:  Yi Zhao; Benzheng Zhang; Qianqian Zhang; Xiaowei Ma; Helin Feng
Journal:  J Zhejiang Univ Sci B       Date:  2021-11-15       Impact factor: 3.066

4.  [MiR-671-5p negatively regulates SMAD3 to inhibit migration and invasion of osteosarcoma cells].

Authors:  Y Hu; D Liang; X Chen; L Chen; J Bai; H Li; C Yin; W Zhong
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-10-20

5.  LncRNA UCA1 accelerates osteosarcoma progression via miR-145 and Wnt/β-catenin pathway.

Authors:  Jian Guan; Juliang He; Shian Liao; Zhenjie Wu; Xiang Lin; Bin Liu; Xiong Qin; Jiachang Tan; Chuangming Huang; Zhenchao Yuan; Hao Mo
Journal:  Am J Transl Res       Date:  2022-09-15       Impact factor: 3.940

6.  Downregulation of hsa_circ_0000885 suppressed osteosarcoma metastasis and progression via regulating E2F3 expression and sponging miR-16-5p.

Authors:  Yanfang Li; Zhiqing Wu; Jianlin Shen
Journal:  Regen Ther       Date:  2022-06-22       Impact factor: 3.651

Review 7.  Targeting Energy Metabolism in Cancer Stem Cells: Progress and Challenges in Leukemia and Solid Tumors.

Authors:  Courtney L Jones; Anagha Inguva; Craig T Jordan
Journal:  Cell Stem Cell       Date:  2021-03-04       Impact factor: 24.633

Review 8.  In vitro three-dimensional cell cultures for bone sarcomas.

Authors:  Javier Munoz-Garcia; Camille Jubelin; Aurélie Loussouarn; Matisse Goumard; Laurent Griscom; Axelle Renodon-Cornière; Marie-Françoise Heymann; Dominique Heymann
Journal:  J Bone Oncol       Date:  2021-07-06       Impact factor: 4.072

9.  Identification and preliminary validation of a four-gene signature to predict metastasis and survival in osteosarcoma.

Authors:  Yiming Zhang; Xuan Lei; Rong He; Lianghao Mao; Pan Jiang; Chenlie Ni; Xinyu Zhong; Zhengyu Yin; Xuan Wu; Dapeng Li; Qiping Zheng
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

10.  Curcumin-Loaded Nanoparticles Impair the Pro-Tumor Activity of Acid-Stressed MSC in an In Vitro Model of Osteosarcoma.

Authors:  Gemma Di Pompo; Margherita Cortini; Roberto Palomba; Valentina Di Francesco; Elena Bellotti; Paolo Decuzzi; Nicola Baldini; Sofia Avnet
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.